17:13 EDT Zai Lab files automatic ordinary shares offering
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Executive officers of Zai Lab ‘do not anticipate selling any shares’ in 2024
- Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints
- Zai Lab says partner Novocure’s Phase 3 trial met primary endpoint
- Zai Lab price target lowered to $66 from $123 at Citi
- Zai Lab Ltd’s New Share Price & Shareholder Rights Risk – A Cause for Worry?